Temozolomide vs. Procarbazine for Glioblastoma
Author Information
Author(s): Yung W K A, Albright R E, Olson J, Fredericks R, Fink K, Prados M D, Brada M, Spence A, Hohl R J, Shapiro W, Glantz M, Greenberg H, Selker R G, Vick N A, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin V A
Primary Institution: Department of Neuro-Oncology, UTMD Anderson Cancer Center
Hypothesis
Is temozolomide more effective than procarbazine in treating glioblastoma multiforme at first relapse?
Conclusion
Temozolomide significantly improved progression-free survival and overall survival compared to procarbazine in patients with glioblastoma multiforme.
Supporting Evidence
- The 6-month progression-free survival rate for temozolomide was 21%, compared to 8% for procarbazine.
- Overall progression-free survival was significantly better with temozolomide, with a median of 12.4 weeks versus 8.32 weeks for procarbazine.
- The 6-month overall survival rate was 60% for temozolomide patients compared to 44% for procarbazine patients.
- Temozolomide had an acceptable safety profile with mostly mild or moderate adverse events.
Takeaway
This study found that a medicine called temozolomide helps people with a type of brain cancer live longer without their cancer getting worse compared to another medicine called procarbazine.
Methodology
A randomized, multicentre, open-label, phase II study comparing temozolomide and procarbazine in patients with glioblastoma multiforme.
Participant Demographics
Adult patients with glioblastoma multiforme at first relapse.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website